‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
Add this event to your calendar:
Outlook  |  Google Calendar  |  Apple Calendar
Scientific Exchange on New Clinical and Real-World Evidence
You are invited to join UCB for a lunchtime Industry Therapeutic Update where we will feature a scientific exchange on new clinical and real-world evidence related to fenfluramine in Dravet and Lennox-Gastaut syndromes. This program will also highlight real-world use of an updated refractory epilepsy screening tool to support identification of Lennox-Gastaut syndrome and conclude with an interactive Q&A.
PANEL OF EXPERTS
David Burdette, MD, FACNS
David Burdette, MD, FACNS Epilepsy Section Chief,
Corewell Health West
Grand Rapids, MI
Amélie Lothe, PhD
Amélie Lothe, PhD Global Medical Community Head,
UCB Rare Epilepsies
Heidi Henninger, MD, FAAN, FAES
Heidi Henninger, MD, FAAN, FAES Epileptologist,
UCB Consultant
Jaya Khushalani, MD, PhD
Jaya Khushalani, MD, PhD HEOR Lead,
UCB Epilepsy & Rare Syndromes
 
This program will aim to meet the following objectives:
  • Characterize the long-term tolerability and global functioning outcomes associated with fenfluramine in patients with Dravet and Lennox-Gastaut syndromes
  • Describe the association between fenfluramine and everyday executive functioning in adults with Lennox-Gastaut syndrome
  • Review real-world healthcare resource utilization and antiseizure medication patterns in patients with Lennox-Gastaut syndrome treated with fenfluramine
  • Explore the role of an updated refractory epilepsy screening tool in identifying Lennox-Gastaut syndrome in real-world practice
PANEL OF EXPERTS
David Burdette, MD, FACNS
 David Burdette, MD, FACNS Epilepsy Section Chief,
Corewell Health West
Grand Rapids, MI
Amélie Lothe, PhD
 Amélie Lothe, PhD Global Medical Community Head,
UCB Rare Epilepsies
Amélie Lothe, PhD
 Heidi Henninger, MD, FAAN, FAES Epileptologist,
UCB Consultant
Jaya Khushalani, MD, PhD
 Jaya Khushalani, MD, PhD HEOR Lead,
UCB Epilepsy & Rare Syndromes
 
This program will aim to meet the following objectives:
  • Characterize the long-term tolerability and global functioning outcomes associated with fenfluramine in patients with Dravet and Lennox-Gastaut syndromes
  • Describe the association between fenfluramine and everyday executive functioning in adults with Lennox-Gastaut syndrome
  • Review real-world healthcare resource utilization and antiseizure medication patterns in patients with Lennox-Gastaut syndrome treated with fenfluramine
  • Explore the role of an updated refractory epilepsy screening tool in identifying Lennox-Gastaut syndrome in real-world practice
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2026 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this program is limited to healthcare professionals. Accordingly, attendance by guests or spouses is not appropriate, and associated expenses will not be reimbursed. Certain state and federal requirements place restrictions on and/or require disclosure of items UCB provides to healthcare professionals, including meals and refreshments. UCB is committed to complying with all legal requirements.
©2026 UCB, Inc., Smyrna, GA 30080. All rights reserved.
US-FA-2600045 		UCB, Inc.
unsubscribe here